Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds BTIG Downgrades Magenta Therapeutics to Neutral

BTIG Downgrades Magenta Therapeutics to Neutral

BTIG analyst Yun Zhong downgrades Magenta Therapeutics (NASDAQ:MGTA) from Buy to Neutral.

byBenzinga Newsdesk

January 26, 2023

1 minute read

BTIG analyst Yun Zhong downgrades Magenta Therapeutics (NASDAQ:MGTA) from Buy to Neutral.

Barclays Maintains Underweight on Coherent, Raises Price Target to $36

By Benzinga Newsdesk

January 23, 7:43 AM

Barclays analyst Tom O'Malley maintains Coherent (NASDAQ:COHR) with a Underweight and raises the price target from $30 to $36.

COHR

News

‘Netflix Signs Up 1.5M U.S. Subscribers for Ad Tier So Far’ – The Information

By Happy Mohamed

July 19, 1:30 PM

https://www.theinformation.com/articles/netflix-signs-up-1-5-million-u-s-subscribers-for-ad-tier-so-far Netflix Signs Up 1.5 Million U.S. Subscribers for Ad Tier So Far Around 1.5 million people in the U.S. have signed

NFLX

Jefferies Upgrades Aligos Therapeutics to Buy, Raises Price Target to $3

By Benzinga Newsdesk

January 6, 6:24 AM

Jefferies analyst Michael Yee upgrades Aligos Therapeutics (NASDAQ:ALGS) from Hold to Buy and raises the price target from $2.5 to $3.

ALGS

News
Tech

Could Samsung Galaxy S24 Come With Generative AI Features? Here’s What We Know

By Rounak Jain

November 2, 8:33 AM

Samsung's Galaxy S24 or the Galaxy Z Fold 6 might be among the first devices to showcase ChatGPT-like AI technology built-in.

GOOG

BTIG Downgrades Magenta Therapeutics to Neutral

Related Posts

Barclays Maintains Underweight on Coherent, Raises Price Target to $36

‘Netflix Signs Up 1.5M U.S. Subscribers for Ad Tier So Far’ – The Information

Jefferies Upgrades Aligos Therapeutics to Buy, Raises Price Target to $3

Could Samsung Galaxy S24 Come With Generative AI Features? Here’s What We Know